Coronavirus Proves Drug Companies To Be Innovators [Forbes]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Forbes
In the midst of the COVID-19 pandemic, many Americans are concerned about loved ones in at-risk groups and the capacity of our hospitals and medical system to address those in need—all while making extraordinary efforts to follow social distancing and work-from-home guidelines. Perhaps the most important ongoing development of the coronavirus, however, is the research and development that drug companies are dedicating to discovering both treatments and vaccines. Some have argued that the pharmaceutical companies are taking advantage of the pandemic to make a quick buck, but that argument strains credulity. It is hard to understate how the pharmaceutical industry is doing its absolute best to find treatments as well as, possibly most importantly, a vaccine to the coronavirus during this time of national emergency. To me, it comes as little surprise that the US biopharmaceutical industry is leading the world right now in vaccines and treatments to COVID-19. To date, they have many clini
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Citigroup Inc.. They set a "neutral" rating and a $895.00 price target on the stock.MarketBeat
- Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease [Yahoo! Finance]Yahoo! Finance
- Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASHGlobeNewswire
- Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales [Yahoo! Finance]Yahoo! Finance
- Regeneron Announces Investor Conference PresentationsGlobeNewswire
REGN
Earnings
- 10/31/24 - Beat
REGN
Sec Filings
- 11/12/24 - Form 4
- 11/5/24 - Form 4
- 11/1/24 - Form 144
- REGN's page on the SEC website